Abstract
Acromegaly is characterized by a high prevalence of cardiovascular complications that account for increased morbidity and mortality. Several studies emphasized the role of GH and IGF-1 excess in cardiac dysfunction. Coexisting factors such as hypertension, glucose tolerance abnormalities and coronary artery disease have a potential role in the progression of the acromegalic cardiomyopathy.
Herein, we review the most relevant pathophysiological, functional and morphological findings in this specific disease.
Similar content being viewed by others
References
Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95–102.
Orme SM, Mcnally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730–2734.
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte A, Pivonello R, Salvatore M, Lombardi G. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin like growth factor1 levels on cardiac performance. J Clin Endocrinol Metab 2001;86(4):1551–1557.
Holdaway IM, Rajasoorya C. Epidemilology of acromegaly. Pituitary 1999;2(1):29–41.
Lopez-Velasco R, Escobar-Morreale H, Vega B, Villa E, Sancho J, Moya-Mur J, Garcia-Robles R. Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab 1997;82(4):1047–1053.
Bruch C, Herrmann B, Schmermund A, Bartel T, Mann K, Erbel R. Impact of disease activity on left ventricular performance in patients with acromegaly. Am Heart J 2002;144(3):538–543.
Fazio S, Cittadini A, Sabatini D, Merola B, Colao A, Biondi B, Longobardi S, Lombardi G, Sacca L. Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J 1997;18(2):181–184.
Lombardi G, Colao A, Ferone D, Marzullo P, Orio F, Longobardi S, Merola B. Effect of growth hormone on cardiac function. Horm Res 1997;48(Suppl 4):38–42.
Lie JT. Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients. Am Heart J 1980;100(1): 41–52.
Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf)2001;54:137–154.
Minniti G, Jaffrain Rea ML, Moroni C, Baldelli R, Ferretti E, Cassone R, Gulino A, Tamburrano G. Echocardiographic evidence for a direct effect of GH/IGF-1 hypersecretion on cardiac mass and function in youg acromegalics. Clinical Endocrinology 1998;49:101–106.
Tokita N, Hasegawa S, Hirata M, Yoshioka J, Yamagushi H, Hori M, Nishimura T. Fluorine-18 FDG myocardial positron emission tomographic findings before and after pituitary adenoma resection in a patient with acromegalic cardiomyopathy. Clin Nucl Med 2000;25(8):619–621.
Jaffrain-Rea ML, Minniti G, Moroni C, Esposito V, Ferretti E, Santoro A, Infusino T, Tamburrano G, Cantore G, Cassone R. Impact of successful transphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 2003; 148(2):193–201.
Baldelli R, Ferretti E, Jaffrain-Rea M, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G. Cardiac effects of slow-release Lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999;84(2):527–532.
Calao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Garciulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85(1):193–199
Nikkila EA, Pelkonen R. Serum lipids in acromegaly. Metabolism 1975;24:829–838.
Takeda R, Tatami R, Ueda K, Sagara H, Nakabayashi H, Mabuchi H. The incidence and pathogenesis of hyperlipidemia in 16 consecutive acromegalic patients. Acta Endocrinologica 1982;100:358–362
Hermaann BL, Bruch C, Saller B, Ferdin S, Dagres N, Ose C, Erbel R, Mann K. Occurence of ventricular late potentials in patients with active acromegaly. Clinical endocrinology 2001;55:201–207.
Cittadini A, Stromer H, Katz S, Clark R, Moses A, Morgan J, Douglas P. Differnetial cardiac effects of growth hormone and insulin-like growth factor 1 in the rat. Circulation 1996;93:800–809.
Ren J, Samson WK, Sowers JR. Insulin-like growth factor 1 as a cardiac hormone: Physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999;31(11):2049–2061.
Mathews LS, Enmberg B, Norsstedt G. Regulation of rat growth hormone receptor gene expression. J Biol Chem 1989;17:9905–9910.
Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin like growth factor 1 increases in early hypertension. Hypertension 1992;19(1):25–32.
Hanson MC, Fath KA, Alexander RW, Delafontaine P.induction of cardiac insulin-like growth factor-1 gene expression in pressure overload hypertrophy. Am J Med Sci 1993;306(2):69–74.
Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995;95(2):619–627.
Fu ML, Tornell J, Schulze W, Hoebeke J, Isaksson OG, Sandstedt J, Hjalmarson A. Myocardial hypertrophy in transgenic mice overexpressing the bovine growth hormone(bGH) gene. I Inter Med 2000;247(5):546–552.
Xu X, Best PM. Decreased transient outward K+ current in ventricular myocytes from acromegalic rats. Am J Physiol 1991;260:H935–H942.
Stromer H, Cittadini A, Douglas PS, Morgan JP. Exogenously administered growth hormone and IGF-1 alter intracellular calcium handling and enhance cardiac performance. J Am Coll Cardiol 1995; February special issue: 282A (Abstract).
Rubin SA, Buttrick P, Malhotra A, Melmed S, Fishbein MC. Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat. J Moll Cell Cardiol 1990;22:429–438.
Mayoux E, Ventura-Clapier R, Timsit J, Behar-Cohen Hoffmann C, Mercadier J-J. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res 1993;72:57–64 (Abstact).
Timsit J, Riou B, Bertherat J, Wisnewsky C, Kato NS, Weisberg AS, Lubetzki J, Lecarpentier Y, Winegrad S, Mercadier JJ. Effect of chronic growth hormone secretion on intrinsic contractility, energetics, isomyosin pattern, and myosine adenosine triphosphatase activity of rat left ventricle. J Clin Invest 1990;86:507–515.
Sasson Z, Rasooly Y, Blesania T, Rasooly I. Insulin resistance is in important determinant of left ventricular mass in the obese. Circulation 1993;88:1431–1436.
Sechen SJ, Dunshea FR, Bauman DE. Somatotropin in lactating cows: Effect on response to epinephrin and insulin. Am J Physiol 1990;258:E582–E588.
Beauville M, Harant I, Crampes F, Riviere D, Tauber MT, Gariigues M. Effect of long-term rhGH administration in GH deficient adults on fat cell epinephrin response. Am J Physiol 1992;263:E467–E472.
Shimomura Y, Lee M, Oku J, Bray GA, Glick Z. Sodium potassium dependent ATP ase in hypophysectomized rats: Response to growth hormone, triiodothyronine, and cortisone. Metabolism 1982;31(3):213–216.
Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism 1990;39(2):133–137.
Bruel A, Oxlund H. Biosyntheic growth hormone increases the collagen deposition rate in rat aorta and heart. Eur J Endocrinol 1995;132:195–199.
Fazio S, Cittadini A, Sabatini D, Merola B, Colao A, Biondi B, Lombardi G, Sacca L. Evidence for biventricular involvement in acromegaly: A doppler echocardiographic study. European Heart Journal 1993;14:26–33.
Fazio S, Cittadini A, Cuocola A, Merola B, Sabatini D, Nicolai E, Colao A, Biondi B, Lombardi G, Sacca L. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab 1994;79:441–446.
Frustaci A, Chimenti C, Setoguchi M, Guerra S, Corsello S, Crea F, Leri A, Kajstura J, Anversa P, Maseri A. Cell death in acromegalic cardiomyopathy. Circulation 1999;23:1426–1434.
Vianna CB, Vieira ML, Mady C, Liberman B, Durazzo AE, Knoepfelmacher M, Salgado LR, Ramires JA. Treatment of acromegaly improves myocardial abnormalities. Am Heart J 2002;143(5):873–876.
Tanaka N, Ryoke T, Hongo M, Mao L, Rockman H, Clark R, Ross Jr J. Effects of growth hormone and IGF-1 on cardiac hypertrophy and gene expression in mice. AJP-Heart and Circulatory Physiology 1998;275(2):393–399.
Vianna CB, Vieira ML, Mady C, Liberman B, Durazzo AE, Knoepfelmacher M, Salgado LR, Ramires JA. Treatment of acromegaly improves myocardial abnormalities. Am Heart J 2002;143(5):873–876.
Manelli F, Desenzani P, Boni E, Bugari G, Negrini F, Romanelli G, Grassi V, Giustina A. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999;2(3):205–210.
Colao, Merola B, Ferone D, Lombardi G. Extensive personal experience: Acromegaly. J Clin Endocrinol Metab 1997;82:2777–2781.
Fazio S, Cittadini A, Biondi B, Palmieri A, Riccio G, Bone F, Oliviero U, Sacca L. Cardiovascular effects of short term growth hormone hypersecretion. J Clin Endocrinol Metab 2000;85(1):179–182.
Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, di Smma C, Bonaduce D, Salvatore M, Lombardi G. Cardiovascular consequences of early onset growth hormone excess. J Clin Endocrinol Metab 2002;87(7):3097–3104.
Thuesen L, Christensen SE, Week J, Orskov H, Henningsen P. A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Medica Scandinavia 1988;223:337–343.
Mercuro G, Zoncu S, Colonna P, Cherchi P, Mariotti S, Pigliaru F, Petrini L, Iliceto S. Cardiac dysfunction in acromegaly: Evidence by pulsed wave tissue doppler imaging. Eur J Endocrinol 2000;143(3):363–369.
Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Vujisic B, Petrovic M, Nikolic-Djurovic M, Simic M, Pekic S, Marinkovic J. High output heart failure in patients with newly diagnosed acromegaly. Am J Med 2002;112(8):610–616.
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999;84(1):17–23.
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G. Cardiovascular effects of depot Long-acting Somatostatin Analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 200;85(9):3132–3140.
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long acting somatostatin analogue octreotide. Clinical Endocrinology 2003;58:169–176.
Wright AD, Hill DM, Lowy C, Froser TR. Mortality in acromegaly. Q J Med 1970;39(153):1–16.
Terzolo M, Matrella C, Boccuzzi A, Luceri S, Borriero M, Reimondo G, Pia A, Rovero E, Paccotti P, Angeli A. Twenty– four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J Endocrinol Invest 1999;22:48–54.
Molitch ME. Clinical manifestations of acromegaly. Endocrin Metab Clin North Am 1992; 21(3):597–614.
Khorsandi M, Fagin JA, Fishbein MC, Forrester JS, Cercek B. Effects of hypophysectomy on vascular insulin like growth factor 1 gene expression after balloon denudation in rats. Atherosclerosis 1992;93:115–122.
Biglieri E, Watlington CO, Forsham PH. Sodium retention with human growth hormone and its subfractions. J Clin Endocrinol Metab 1961;21:361–370.
Ho KK, O Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. Endocr J 1996;43(Suppl):S57–S63.
Ezzat S, Forster MJ, Bertchold P, redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features of acromegaly in 500 patients. Medicine(Baltimore) 1994;73:233–240.
Jaffrain-rea ML, Morono C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R, Tamburrano G. Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology 2001;54:189–195.
Pinzone JJ, Katznelson L, Klibanski A. Acromegalic heart disease. The Endocrinologist 1998;8:273–278.
Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15(5):555–573.
Schiavon F, Maffei P, Martini C, de Carlo E, Fais C, Todesco S, Sicolo N. Morphologic study of microcirculation in acromegaly by capilloroscopy. J Clin Endocrinol Metab 1999;84:3151–3155.
Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G. Increased arterial intima-medi thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 2001;54(4):515–524.
Otsuki M, Kasyama S, Hiroyasu Y, Saito H, Sumitani S, Kouhara H, Saitoh Y, Ohnishi T, Arita N. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clinical Endocrinology 2001;54:791–796.
Pfeifer M, Verhovec R, Zizek B. Growth hormone and atherosclerosis: Changes in morphology and function of major arteries during GH treatment. Growth Horm IGF Res 1999;9(Suppl A):25–30.
Boger RH. Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. J Endocrinol Invest 1999;22(5 Suppl):75–81.
Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin like growth factor I induced nitric oxide production by endothelial cells. Kidney International 1994;45:598–604.
Irving RJ, Carson MN, Webb DJ, Walker BR. Peripheral vascular structure and function in men with contrasting GH levels. J Clin Endocrinol Metab 2002; 87 (7):3309–3314.
Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M. Alterations of homeostatic and fibrinolytic markers in adult patients with growth hormonr deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 2000;108(7):486–492.
Matturi L, Varesi C, Nappo A, Cuttin MS, Rossi L. Sudden cardiac death in acromegaly. Anatomopathological observation of a case. Minnerva Med 1998;89(7-8):287–291.
Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J. Arrythmia profile in acromegaly. European Heart journal 1992;13:51–56.
Rodrigues EA, Caruana MP, Lahiri A, Nabarro JD, Jacobs HS, Raftery EB. Subclinical cardiac dysfunction in acromegaly evidence for a specific disease of heart muscle. British Heart Journal 1989;62:185–194.
Ripa S, Caccano L, Amati PC, Bologna F, Piovaccari GC. Severe mitral insufficiency caused by the rupture of the chordae tendinae in acromegaly. Report of a case. Ital Heart J 2001 Sep;2(9 Suppl):1020–1022.
Ohtsuka G, Aomi S, Koyanagi H, Tsukui H, Tomizawa Y, Hashimoto A, Sakomura Y. Heart valve operation in acromegaly. Annals of Thoracic Surgery 1997;64:390-393.
Ondreyco SM, Lewis HD Jr, Hartman CR. Myxomatous degeneration and cystic medial necrosis associated with acromegaly. Arch Intern Med 1980;140(4):547–549.
Marzullo P, Cuocolo A, Ferone D, Pivonello R, Salvatore M, Lombardi G, Colao A. Cardiac effect of thyrotoxicosis in acromegaly. J Clin Endocrinol Metab 2000;85:1426–1432.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matta, M., Caron, P. Acromegalic Cardiomyopathy: A Review of the Literature. Pituitary 6, 203–207 (2003). https://doi.org/10.1023/B:PITU.0000023427.31609.a2
Issue Date:
DOI: https://doi.org/10.1023/B:PITU.0000023427.31609.a2